Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modalis TherapeuticsTSE:4883 +3.03%20 Quick Ratio is 21.46 as of Dec. 2025, which is 27% below its 10-year median of 29.40. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 999 Drug Manufacturers companies, Modalis Therapeutics ranks better than 98.7% on this metric.
Modalis Therapeutics has a quick ratio of 21.46. It generally indicates good short-term financial strength.
The historical rank and industry rank for Modalis Therapeutics's Quick Ratio or its related term are showing as below:
TSE:4883'
s Quick Ratio Range Over the Past 10 Years
Min: 9.84 Med: 29.4 Max: 93.51
Current: 25.02
During the past 8 years, Modalis Therapeutics's highest Quick Ratio was 93.51. The lowest was 9.84. And the median was 29.40.
TSE:4883's Quick Ratio is ranked better than 98.7% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs TSE:4883: 25.02
Modalis Therapeutics (TSE:4883) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Modalis Therapeutics Quick Ratio Related Terms
Modalis Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Modalis Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modalis Therapeutics Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Modalis Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Modalis Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modalis Therapeutics (TSE:4883) has a Quick Ratio of 21.46 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Modalis Therapeutics and its competitors. This is 27% below median its historical median of 29.40. Over the past decade, Modalis Therapeutics' Quick Ratio has ranged from 9.84 to 93.51. According to the industry distribution chart, Modalis Therapeutics ranks #13 out of 999 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Modalis Therapeutics' Quick Ratio too high?
Modalis Therapeutics' current Quick Ratio of 21.46 is 27% below median its 10-year median of 29.40. Over the past 10 years, this metric has ranged from a low of 9.84 to a high of 93.51. The Drug Manufacturers industry median Quick Ratio is 1.45. Modalis Therapeutics' value of 21.46 is 1380% above this industry median. Based on the distribution chart, Modalis Therapeutics ranks #13 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #13 out of 999 companies for Quick Ratio. This places Modalis Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Modalis Therapeutics' value of 21.46 is 1380% above this benchmark. Historically, Modalis Therapeutics' own Quick Ratio has ranged from 9.84 to 93.51 over the past decade. While the company's 10-year median is 29.40 vs. the industry median of 1.45, Modalis Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modalis Therapeutics's current Quick Ratio of 21.46 is 1380% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Modalis Therapeutics and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modalis Therapeutics's current Quick Ratio is 21.46, which is 27% below median its own 10-year median of 29.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Quick Ratio of 21.46. The current Quick Ratio is 21.46, which is 27% below median its 10-year median of 29.40 and 1380% above the Drug Manufacturers industry median of 1.45. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Quick Ratio is 21.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score
Get the complete analysis for TSE:4883
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4883 has been successfully added to your 
